⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2096146 | 0.80 | — | — | |
| SCHEMBL9963344 | 0.80 | NOTUM (0.38) | — | |
| SCHEMBL31693584 | 0.80 | — | — | |
| SCHEMBL2096145 | 0.80 | — | — | |
| SCHEMBL16182214 | 0.80 | — | — | |
| SCHEMBL25092262 | 0.80 | — | — | |
| SCHEMBL17298833 | 0.80 | — | — | |
| SCHEMBL17359182 | 0.77 | NOTUM (0.36) | — | |
| SCHEMBL12259298 | 0.75 | CTSK (0.39) | — | |
| SCHEMBL2096416 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 784 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122103056-A | Continuous synthesis method of amicarbazone intermediate 5-isopropyl-1, 3, 4-oxadiazole-2 (3H) -ketone | — | 2026-05-29 | — | — | CN | disclosed |
| CN-122103056-A | Continuous synthesis method of amicarbazone intermediate 5-isopropyl-1, 3, 4-oxadiazole-2 (3H) -ketone | — | 2026-05-29 | — | — | CN | disclosed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| WO-2024137674-A2 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | AMGEN INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024089191-A1 | MICROBIOCIDAL HETEROBICYCLIC DIHYDROOXADIAZINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-11919915-B2 | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations | AGIOS PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2004014882-A2 | PROTEASOME INHIBITORS : PEPTIDE DERIVATIVES HAVING C-TERMINAL HETEROARYL GROUPS | AXYS PHARMACEUTICALS (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030130326-A1 | 1,3,4-oxadiazole derivatives and process for producing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-10 | — | — | US | disclosed |
| US-6492348-B1 | Adenosine derivatives | SMITHKLINE BEECHAM CORPORATION | 2002-12-10 | — | — | US | disclosed |
| EP-1253144-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-10-30 | — | — | EP | disclosed |
| CN-1143958-A | (4,4-difluorobut-3-enylthio-)-substituted heterocyclic or carbocyclic ring compounds | ZENECA LTD (GB) | 1997-02-26 | — | — | CN | disclosed |